Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report

Research output: Contribution to journalArticle

Abstract

Background: Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using the drug in a metronomic fashion, potentially able to combine anthracyclines efficacy to a low toxicity profile. Patients and methods: In a case-series report carried out in both anthracycline-naive and pre-treated metastatic breast cancer patients, we tested feasibility, clinical efficacy and tolerability of PLD administered with a novel metronomic schedule of 20mg/m2 i.v. every two weeks. Results: 52 patients were enrolled and 45 were evaluated. Forty-four patients were assessed for either response or toxicity. Eight patients (18%) had partial responses (PR) and 17 (39%) stable disease (SD), with a clinical benefit (CB) of 45% (95% CI: 30.3%-59.7%). Nineteen patients (43%) had progressive disease (PD). Neither grade 3 nor grade 4 haematological or clinical side effects were recorded, except for 2 patients with grade 3 palmar-plantar erythrodysesthesia (PPE). No cardiac toxicity was recorded. Conclusion: Metronomic administration of PLD is a feasible and active treatment for extensively pre-treated metastatic breast cancer patients, alternative to classic anthracyclines, balancing clinical efficacy with a good quality of life in terms of reduced side effects and low personal costs for the patient.

Original languageEnglish
Pages (from-to)33-37
Number of pages5
JournalBreast
Volume19
Issue number1
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Metronomic Administration
Breast Neoplasms
Anthracyclines
liposomal doxorubicin

Keywords

  • Advanced breast cancer
  • Metronomic chemotherapy
  • Pegylated liposomal-doxorubicin

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

@article{39478bd981084d22a66c78b167a9b1b0,
title = "Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report",
abstract = "Background: Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using the drug in a metronomic fashion, potentially able to combine anthracyclines efficacy to a low toxicity profile. Patients and methods: In a case-series report carried out in both anthracycline-naive and pre-treated metastatic breast cancer patients, we tested feasibility, clinical efficacy and tolerability of PLD administered with a novel metronomic schedule of 20mg/m2 i.v. every two weeks. Results: 52 patients were enrolled and 45 were evaluated. Forty-four patients were assessed for either response or toxicity. Eight patients (18{\%}) had partial responses (PR) and 17 (39{\%}) stable disease (SD), with a clinical benefit (CB) of 45{\%} (95{\%} CI: 30.3{\%}-59.7{\%}). Nineteen patients (43{\%}) had progressive disease (PD). Neither grade 3 nor grade 4 haematological or clinical side effects were recorded, except for 2 patients with grade 3 palmar-plantar erythrodysesthesia (PPE). No cardiac toxicity was recorded. Conclusion: Metronomic administration of PLD is a feasible and active treatment for extensively pre-treated metastatic breast cancer patients, alternative to classic anthracyclines, balancing clinical efficacy with a good quality of life in terms of reduced side effects and low personal costs for the patient.",
keywords = "Advanced breast cancer, Metronomic chemotherapy, Pegylated liposomal-doxorubicin",
author = "E. Munzone and {Di Pietro}, A. and A. Goldhirsch and I. Minchella and E. Verri and {Cossu Rocca}, M. and C. Marenghi and G. Curigliano and D. Radice and L. Adamoli and F. Nol{\`e}",
year = "2010",
month = "2",
doi = "10.1016/j.breast.2009.10.003",
language = "English",
volume = "19",
pages = "33--37",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients

T2 - A mono-institutional case-series report

AU - Munzone, E.

AU - Di Pietro, A.

AU - Goldhirsch, A.

AU - Minchella, I.

AU - Verri, E.

AU - Cossu Rocca, M.

AU - Marenghi, C.

AU - Curigliano, G.

AU - Radice, D.

AU - Adamoli, L.

AU - Nolè, F.

PY - 2010/2

Y1 - 2010/2

N2 - Background: Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using the drug in a metronomic fashion, potentially able to combine anthracyclines efficacy to a low toxicity profile. Patients and methods: In a case-series report carried out in both anthracycline-naive and pre-treated metastatic breast cancer patients, we tested feasibility, clinical efficacy and tolerability of PLD administered with a novel metronomic schedule of 20mg/m2 i.v. every two weeks. Results: 52 patients were enrolled and 45 were evaluated. Forty-four patients were assessed for either response or toxicity. Eight patients (18%) had partial responses (PR) and 17 (39%) stable disease (SD), with a clinical benefit (CB) of 45% (95% CI: 30.3%-59.7%). Nineteen patients (43%) had progressive disease (PD). Neither grade 3 nor grade 4 haematological or clinical side effects were recorded, except for 2 patients with grade 3 palmar-plantar erythrodysesthesia (PPE). No cardiac toxicity was recorded. Conclusion: Metronomic administration of PLD is a feasible and active treatment for extensively pre-treated metastatic breast cancer patients, alternative to classic anthracyclines, balancing clinical efficacy with a good quality of life in terms of reduced side effects and low personal costs for the patient.

AB - Background: Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using the drug in a metronomic fashion, potentially able to combine anthracyclines efficacy to a low toxicity profile. Patients and methods: In a case-series report carried out in both anthracycline-naive and pre-treated metastatic breast cancer patients, we tested feasibility, clinical efficacy and tolerability of PLD administered with a novel metronomic schedule of 20mg/m2 i.v. every two weeks. Results: 52 patients were enrolled and 45 were evaluated. Forty-four patients were assessed for either response or toxicity. Eight patients (18%) had partial responses (PR) and 17 (39%) stable disease (SD), with a clinical benefit (CB) of 45% (95% CI: 30.3%-59.7%). Nineteen patients (43%) had progressive disease (PD). Neither grade 3 nor grade 4 haematological or clinical side effects were recorded, except for 2 patients with grade 3 palmar-plantar erythrodysesthesia (PPE). No cardiac toxicity was recorded. Conclusion: Metronomic administration of PLD is a feasible and active treatment for extensively pre-treated metastatic breast cancer patients, alternative to classic anthracyclines, balancing clinical efficacy with a good quality of life in terms of reduced side effects and low personal costs for the patient.

KW - Advanced breast cancer

KW - Metronomic chemotherapy

KW - Pegylated liposomal-doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=77951885289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951885289&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2009.10.003

DO - 10.1016/j.breast.2009.10.003

M3 - Article

C2 - 19884008

AN - SCOPUS:77951885289

VL - 19

SP - 33

EP - 37

JO - Breast

JF - Breast

SN - 0960-9776

IS - 1

ER -